Therapeutic targeting of human immunodeficiency virus type-1 latency: current clinical realities and future scientific possibilities
- PMID: 11164503
- DOI: 10.1016/s0166-3542(00)00133-9
Therapeutic targeting of human immunodeficiency virus type-1 latency: current clinical realities and future scientific possibilities
Abstract
Factors affecting HIV-1 latency present formidable obstacles for therapeutic intervention. As these obstacles have become a clinical reality, even with the use of potent anti-retroviral regimens, the need for novel therapeutic strategies specifically targeting HIV-1 latency is evident. However, therapeutic targeting of HIV-1 latency requires an understanding of the mechanisms regulating viral quiescence and activation. These mechanisms have been partially delineated using chronically infected cell models and, clearly, HIV-1 activation from latency involves several key viral and cellular components. Among these distinctive therapeutic targets, cellular factors involved in HIV-1 transcription especially warrant further consideration for rational drug design. Exploring the scientific possibilities of new therapies targeting HIV-1 latency may hold new promise of eventual HIV-1 eradication.
Similar articles
-
Understanding HIV latency: the road to an HIV cure.Annu Rev Med. 2015;66:407-21. doi: 10.1146/annurev-med-092112-152941. Annu Rev Med. 2015. PMID: 25587657 Free PMC article. Review.
-
Preclinical shock strategies to reactivate latent HIV-1: an update.Curr Opin HIV AIDS. 2016 Jul;11(4):388-93. doi: 10.1097/COH.0000000000000288. Curr Opin HIV AIDS. 2016. PMID: 27259046 Review.
-
Underlying mechanisms of HIV-1 latency.Virus Genes. 2017 Jun;53(3):329-339. doi: 10.1007/s11262-017-1443-1. Epub 2017 Mar 3. Virus Genes. 2017. PMID: 28258391 Review.
-
Effects of diterpenes from latex of Euphorbia lactea and Euphorbia laurifolia on human immunodeficiency virus type 1 reactivation.Phytochemistry. 2010 Feb;71(2-3):243-8. doi: 10.1016/j.phytochem.2009.10.005. Epub 2009 Nov 10. Phytochemistry. 2010. PMID: 19897215
-
The role of latency reversal agents in the cure of HIV: A review of current data.Immunol Lett. 2018 Apr;196:135-139. doi: 10.1016/j.imlet.2018.02.004. Epub 2018 Feb 7. Immunol Lett. 2018. PMID: 29427743 Review.
Cited by
-
HIV reproducibly establishes a latent infection after acute infection of T cells in vitro.EMBO J. 2003 Apr 15;22(8):1868-77. doi: 10.1093/emboj/cdg188. EMBO J. 2003. PMID: 12682019 Free PMC article.
-
Curcumin inhibits ultraviolet light induced human immunodeficiency virus gene expression.Mol Cell Biochem. 2003 Dec;254(1-2):289-97. doi: 10.1023/a:1027393719610. Mol Cell Biochem. 2003. PMID: 14674708
-
Primary cell model for activation-inducible human immunodeficiency virus.J Virol. 2007 Jul;81(14):7424-34. doi: 10.1128/JVI.02838-06. Epub 2007 May 2. J Virol. 2007. PMID: 17475639 Free PMC article.
-
Mouse serum factor(s) down-modulate the CD4 and CXCR4 molecules on human T cells conferring resistance to HIV infection in NOG mice.Med Microbiol Immunol. 2005 Aug;194(4):175-80. doi: 10.1007/s00430-004-0234-1. Epub 2005 Jan 15. Med Microbiol Immunol. 2005. PMID: 15654627
-
Identification of T cell-signaling pathways that stimulate latent HIV in primary cells.Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12955-60. doi: 10.1073/pnas.2233345100. Epub 2003 Oct 20. Proc Natl Acad Sci U S A. 2003. PMID: 14569007 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
